MCRB (STOCKS)
Seres Therapeutics, Inc.
$14.090000
-0.220000 (-1.54%)
Prev close: $14.310000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Thomas J. DesRosier
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $129.73M
- Employees
- 103
- P/E (TTM)
- 23.57
- P/B (TTM)
- 2.87
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.94 | $1.31 | -0.3656 | -28.00% |
|
Jun 2025 (Q2)
|
$-2.27 | $-2.54 | +0.2724 | +10.71% |
|
Mar 2025 (Q1)
|
$-2.96 | $-0.55 | -2.4092 | -437.40% |
|
Dec 2024 (Q4)
|
$-2.00 | $-4.02 | +2.0153 | +50.19% |
Financial Statements
| Revenues | $351.00K |
| Nonoperating Income/Loss | $108.82M |
| Operating Expenses | $103.78M |
| Research and Development | $50.22M |
| Other Operating Expenses | $53.56M |
| Operating Income/Loss | -$103.43M |
| Income/Loss From Continuing Operations After Tax | $5.39M |
| Income/Loss From Continuing Operations Before Tax | $5.39M |
| Income/Loss From Discontinued Operations Net Of Tax | $0.00 |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | $5.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $5.39M |
| Net Income/Loss Available To Common Stockholders, Basic | $5.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.31 |
| Diluted Earnings Per Share | $0.30 |
| Basic Average Shares | 156,631,415 |
| Diluted Average Shares | 156,640,794 |
| Assets | $143.47M |
| Current Assets | $51.53M |
| Noncurrent Assets | $91.95M |
| Fixed Assets | $8.58M |
| Other Non-current Assets | $83.37M |
| Liabilities | $99.78M |
| Current Liabilities | $22.43M |
| Accounts Payable | $1.68M |
| Wages | $4.44M |
| Other Current Liabilities | $16.31M |
| Noncurrent Liabilities | $77.35M |
| Equity | $43.70M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $43.70M |
| Liabilities And Equity | $143.47M |
| Net Cash Flow From Operating Activities | -$23.06M |
| Net Cash Flow From Operating Activities, Continuing | -$23.06M |
| Net Cash Flow From Investing Activities | -$313.00K |
| Net Cash Flow From Investing Activities, Continuing | -$313.00K |
| Net Cash Flow From Financing Activities | $2.98M |
| Net Cash Flow From Financing Activities, Continuing | $2.98M |
| Net Cash Flow | -$20.39M |
| Net Cash Flow, Continuing | -$20.39M |
| Comprehensive Income/Loss | $5.39M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $5.39M |
| Other Comprehensive Income/Loss | $136.00K |